Digital Content 
NEWS #PharmaBuzz
27 Dec 2025
// INDPHARMAPOST
https://www.indianpharmapost.com/drug-approval/chugais-tecentriq-gets-green-light-in-japan-for-hard-to-treat-thymic-carcinoma-18691
19 Nov 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20251119270996/en/KaliVir-Immunotherapeutics-Announces-Clinical-Trial-Collaboration-and-Supply-Agreement-with-Roche-to-Evaluate-VET3-TGI-in-Combination-with-Atezolizumab-Tecentriq-in-Advanced-Solid-Tumors
07 Nov 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/11/07/3183723/0/en/Xilio-Therapeutics-Announces-Late-Breaking-Phase-2-Data-for-Vilastobart-in-Patients-with-MSS-mCRC-and-High-Plasma-Tumor-Mutational-Burden-at-Society-for-Immunotherapy-of-Cancer-SIT.html
07 Nov 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/11/07/3183720/0/en/Xilio-Therapeutics-Highlights-Portfolio-of-Differentiated-Masked-Immunotherapies-at-Society-for-Immunotherapy-of-Cancer-SITC-40th-Annual-Meeting.html
30 Oct 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/10/30/3177502/0/en/Xilio-Therapeutics-to-Present-Phase-2-Data-for-Vilastobart-Highlighting-Response-Rate-in-Patients-with-MSS-mCRC-and-High-Plasma-Tumor-Mutational-Burden-as-a-Late-Breaking-Presentat.html
21 Oct 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/10/21/3169954/0/en/Nxera-s-Partner-Cancer-Research-UK-Presents-Data-from-Successfully-Completed-Phase-1-Clinical-Trial-of-Cancer-Immunotherapy-Drug-HTL0039732-at-ESMO.html
Share